Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys

Pharmacology Biochemistry and Behavior

Volumn 85, Issue 4, 2006, Pages 744-751

  Mello, Nancy K ^a   Negus, S Stevens ^a   Rice, Kenner C ^b   Mendelson, Jack H ^a  

^a MCLEAN HOSPITAL   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Antalarmin; Cocaine discrimination; Cocaine self administration; CRF1 antagonist; HPA axis

Indexed keywords

ANTALARMIN; COCAINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; COCAINE DEPENDENCE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SELF ADMINISTRATION; FEMALE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; RHESUS MONKEY; SEDATION; STRESS; ANIMAL; DRUG ANTAGONISM; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MACACA; PATHOPHYSIOLOGY; PERCEPTIVE DISCRIMINATION;

MACACA MULATTA;

ANIMALS; COCAINE; COCAINE-RELATED DISORDERS; CORTICOTROPIN-RELEASING HORMONE; DISCRIMINATION (PSYCHOLOGY); FEMALE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MACACA MULATTA; MALE; PITUITARY-ADRENAL SYSTEM; PYRIMIDINES; PYRROLES; SELF ADMINISTRATION;

EID: 33846556879     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.11.008     Document Type: Article

References (52)

1. Ayala A.R., Pushkas J., Higley J.D., Ronsaville D., Gold P.W., Chrousos G.P., et al. Behavioral, adrenal, and sympathetic responses to long-term administration of an oral corticotrophin-releasing hormone receptor antagonist in a primate stress paradigm. J Clin Endocrinol Metab 89 (2004) 5729-5737
2. Bossert J., Ghitza U., Lu L., Epstein D.H., and Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol 526 (2005) 36-50
3. Broadbear J.H., Winger G., Cicero T.J., and Woods J.H. Effects of response contingent and noncontingent cocaine injection on hypothalamic-pituitary-adrenal activity in rhesus monkeys. J Pharmacol Exp Ther 290 (1999) 393-402
4. Broadbear J.H., Winger G., Cicero T.J., and Woods J.H. Effects of self-administered cocaine on plasma adrenocorticotropic hormone and cortisol in male rhesus monkeys. J Pharmacol Exp Ther 289 (1999) 1641-1647
5. Broadbear J.H., Winger G., and Woods J.H. Cocaine-reinforced responding in rhesus monkeys: Pharmacological attenuation of the hypothalamic-pituitary-adrenal axis response. J Pharmacol Exp Ther 290 (1999) 1347-1355
6. Broadbear J.H., Winger G., Rivier J.E., Rice K.C., and Woods J.H. Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Neuropsychopharmacology 29 (2004) 1112-1121
7. Chen C. Recent advances in small molecule antagonists of the corticotropin-releasing factor type-1 receptor - focus on pharmacology and pharmacokinetics. Curr Med Chem 13 (2006) 1261-1282
8. Deak T., Nguyen K.T., Ehrlich A.L., Watkins L.R., Spencer R.L., Maier S.F., et al. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140 (1999) 79-86
9. Deroche V., Marinelli M., Le Moal M., and Piazza P.V. Glucocorticoids and behavioral effects of psychostimulants. II: cocaine intravenous self-administration and reinstatement depend on glucocorticoid levels. J Pharmacol Exp Ther 281 (1997) 1401-1407
10. Erb S., Shaham Y., and Stewart J. The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. J Neurosci 18 (1998) 5529-5536
11. Farrell M., Howes S., Taylor C., Lewis G., Jenkins R., Bebbington P., et al. Substance misuse and psychiatric comorbidity: an overview of the OPCS national psychiatric morbidity survey. Addict Behav 23 (1998) 909-918
12. Ghitza, UE, Gray, SM, Epstein, DH, Rice, K, Shaham, Y. The anxiogenic drug Yohimbine reinstates palatable food seeking in a rat relapse model: a role of CRF1 receptors. Neuropsychopharmacology, in press.
13. Goeders N.E. A neuroendocrine role in cocaine reinforcement. Psychoneuroendocrinology 22 (1997) 237-259
14. Goeders N.E. Stress and cocaine addiction. J Pharmacol Exp Ther 301 (2002) 785-789
15. Goeders N.E. The HPA axis and cocaine reinforcement. Psychoneuroendocrinology 27 (2002) 13-33
16. Goeders N.E., and Guerin G.F. Effects of the CRH receptor antagonist CP-154,526 on intravenous cocaine self-administration in rats. Neuropsychopharmacology 23 (2000) 577-586
17. Goeders N.E., and Guerin G.F. Role for corticosterone in intravenous cocaine self-administration in rats. Neuroendocrinology 64 (1996) 337-348
18. Gold P.W., Goodwin F.K., and Chrousos G.P. Clinical and biomedical manifestations of depression: relationship to the neurobiology of stress (Part I). N Engl J Med 319 (1988) 348-353
19. Gold P.W., Goodwin F.K., and Chrousos G.P. Clinical and biomedical manifestations of depression: relationship to the neurobiology of stress (Part II). N Engl J Med 319 (1988) 413-420
20. Grammatopoulos D.K., and Chrousos G.P. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 13 (2002) 436-444
21. Habib K.E., Weld K.P., Rice K.C., Pushkas J., Champoux M., Listwak S., et al. Oral administration of a corticotrophin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci U S A 97 (2000) 6079-6084
22. Heidbreder C.A., and Hagan J.J. Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving. Curr Opin Pharmacol 5 (2005) 107-118
23. Holsboer F. Corticotropin-releasing hormone modulators and depression. Curr Opin Investig Drugs 4 (2003) 46-50
24. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 (2000) 477-501
25. Kehne J., and De Lombaert S. Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr Drug Targets CNS Neurol Disord 1 (2002) 467-493
26. Koob G.F. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 46 (1999) 1167-1180
27. Koob G.F., Ahmed S.H., Boutrel B., Chen S.A., Kenny P.J., Markou A., et al. Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 27 (2004) 739-749
28. Line S.W., Markowitz H., Morgan K.N., and Strong S. Evaluation of attempts to enrich the environment of single-caged non-human primates. In: Driscoll J.W. (Ed). Animal Care and Use in Behavioral Research: Regulations, Issues, and Applications (1989), National Agricultural Library, Beltsville, MD 103-117
29. Lu L., Liu Z., Huang M., and Zhang Z. Dopamine-dependent responses to cocaine depend on corticotropin-releasing factor receptor subtypes. J Neurochem 84 (2003) 1378-1386
30. Mantsch, JR, Katz, ES. Elevation of glucocorticoids is necessary but not sufficient for the escalation of cocaine self-administration by chronic electric footshock stress in rats. Neuropsychopharmacology in press.
31. Mantsch J.R., Schlussman S.D., Ho A., and Kreek M.J. Effects of cocaine self-administration on plasma corticosterone and prolactin in rats. J Pharmacol Exp Ther 294 (2000) 239-247
32. Marinelli M., and Piazza P.V. Interaction between glucocorticoid hormones, stress and psychostimulant drugs. Eur J Neurosci 16 (2002) 387-394
33. Mello N.K., and Mendelson J.H. Cocaine, hormones and behavior: clinical and preclinical studies. In: Pfaff D.W., Arnold A.P., Etgen A.M., Fahrbach S.E., and Rubin R.T. (Eds). Hormones, Brain and Behavior (2002), Academic Press, New York 665-745
34. Mello N.K., and Negus S.S. Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286 (1998) 812-824
35. Mendelson J.H., Mello N.K., Sholar M.B., Siegel A.J., Mutschler N., and Halpern J. Temporal concordance of cocaine effects on mood states and neuroendocrine hormones. Psychoneuroendocrinology 27 (2002) 71-82
36. Mendelson J.H., Mello N.K., Teoh S.K., Lukas S.E., Phipps W., Ellingboe J., et al. Human studies on the biological basis of reinforcement: a neuroendocrine perspective. In: O'Brien C.P., and Jaffe J.H. (Eds). Addictive States (1992), Raven Press, Ltd., New York 131-155
37. Mendelson J.H., Sholar M.B., Mutschler N.H., Jaszyna-Gasior M., Goletiani N.V., Siegel A.J., et al. Effects of intravenous cocaine and cigarette smoking on luteinizing hormone, testosterone and prolactin in men. J Pharmacol Exp Ther 307 (2003) 339-348
38. Mendelson J.H., Sholar M.B., Goletiani N.V., Siegel A.J., and Mello N.K. Effects of low and high nicotine cigarette smoking on mood states and the HPA axis in men. Neuropsychopharmacology 30 (2005) 1751-1763
39. Owens M.J., and Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacological Rev 143 (1991) 425-473
40. Owens M.J., and Nemeroff C.B. Corticotropin-releasing factor antagonists in affective disorders. Expert Opin Investig Drugs 8 (1999) 1849-1858
41. Piazza P.V., and LeMoal M. Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Ann Rev Pharmacol Toxicol 36 (1996) 359-378
42. Seymour P.A., Schmidt A.W., and Schulz D.W. The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev 9 (2003) 57-96
43. Shaham Y., Funk D., Erb S., Brown T.J., Walker C.D., and Stewart J. Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats. J Neurosci 17 (1997) 2605-2614
44. Shaham Y., Erb S., Leung S., Buczek Y., and Stewart J. CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology (Berl) 137 (1998) 184-190
45. Shaham Y., Erb S., and Stewart J. Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Rev 33 (2000) 13-33
46. Sinha R. How does stress increase risk of drug abuse and relapse?. Psychopharmacology 158 (2001) 343-359
47. Sinha R., Garcia M., Paliwal P., Kreek M.J., and Rounsaville B.J. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychatry 63 (2006) 324-331
48. 1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 30 (2005) 90-98
49. Volkow N.D. Drug abuse and mental illness: progress in understanding comorbidity. Am J Psychiatry 158 (2001) 1181-1183
50. Wang B., Shaham Y., Zitzman Y., Azari S., Wise R.A., and You Z.B. Cocaine experience establishes control of midbrain glutamate and dopamine by corticotropin-releasing factor; a role in stress-induced relapse to drug seeking. J Neurosci 25 (2005) 5389-5396
51. Webster E.L., Lewis D.B., Torpy D.J., Zachman E.K., Rice K.C., and Chrousos G.P. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137 (1996) 5747-5750
52. Zorrilla E.P., Valdez G.R., Nozulak J., Koob G.F., and Markou A. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 952 (2002) 188-199